658 related articles for article (PubMed ID: 32229706)
1. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?
Sargiacomo C; Sotgia F; Lisanti MP
Aging (Albany NY); 2020 Mar; 12(8):6511-6517. PubMed ID: 32229706
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32862840
[TBL] [Abstract][Full Text] [Related]
4. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
5. A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic.
Tripathy S; Dassarma B; Roy S; Chabalala H; Matsabisa MG
Int J Antimicrob Agents; 2020 Aug; 56(2):106028. PubMed ID: 32450198
[TBL] [Abstract][Full Text] [Related]
6. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
7. Potential COVID-19 therapeutics from a rare disease: weaponizing lipid dysregulation to combat viral infectivity.
Sturley SL; Rajakumar T; Hammond N; Higaki K; Márka Z; Márka S; Munkacsi AB
J Lipid Res; 2020 Jul; 61(7):972-982. PubMed ID: 32457038
[TBL] [Abstract][Full Text] [Related]
8. Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19.
Sun J; Chen Y; Fan X; Wang X; Han Q; Liu Z
Postgrad Med; 2020 Sep; 132(7):604-613. PubMed ID: 32496926
[TBL] [Abstract][Full Text] [Related]
9. The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications.
Ballout RA; Sviridov D; Bukrinsky MI; Remaley AT
FASEB J; 2020 Jun; 34(6):7253-7264. PubMed ID: 32367579
[TBL] [Abstract][Full Text] [Related]
10. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
[TBL] [Abstract][Full Text] [Related]
11. Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2
Weston S; Coleman CM; Haupt R; Logue J; Matthews K; Li Y; Reyes HM; Weiss SR; Frieman MB
J Virol; 2020 Oct; 94(21):. PubMed ID: 32817221
[TBL] [Abstract][Full Text] [Related]
12. Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic.
Brufsky A
J Med Virol; 2020 Jul; 92(7):770-775. PubMed ID: 32293710
[TBL] [Abstract][Full Text] [Related]
13. COVID-2019: update on epidemiology, disease spread and management.
Sahu KK; Mishra AK; Lal A
Monaldi Arch Chest Dis; 2020 Apr; 90(1):. PubMed ID: 32297723
[TBL] [Abstract][Full Text] [Related]
14. Candidate drugs against SARS-CoV-2 and COVID-19.
McKee DL; Sternberg A; Stange U; Laufer S; Naujokat C
Pharmacol Res; 2020 Jul; 157():104859. PubMed ID: 32360480
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening.
Zhao X; Jiang Y; Zhao Y; Xi H; Liu C; Qu F; Feng X
Eur J Clin Microbiol Infect Dis; 2020 Jul; 39(7):1209-1220. PubMed ID: 32328850
[TBL] [Abstract][Full Text] [Related]
16. Direct SARS-CoV-2 infection of the heart potentiates the cardiovascular sequelae of COVID-19.
Bose RJC; McCarthy JR
Drug Discov Today; 2020 Sep; 25(9):1559-1560. PubMed ID: 32592868
[No Abstract] [Full Text] [Related]
17. Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?
Sanchis-Gomar F; Lavie CJ; Morin DP; Perez-Quilis C; Laukkanen JA; Perez MV
Am J Cardiovasc Drugs; 2020 Oct; 20(5):413-418. PubMed ID: 32737841
[TBL] [Abstract][Full Text] [Related]
18. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect.
Andreani J; Le Bideau M; Duflot I; Jardot P; Rolland C; Boxberger M; Wurtz N; Rolain JM; Colson P; La Scola B; Raoult D
Microb Pathog; 2020 Aug; 145():104228. PubMed ID: 32344177
[TBL] [Abstract][Full Text] [Related]
19. COVID-19: is there a link between the course of infection and pharmacological agents in diabetes?
Filardi T; Morano S
J Endocrinol Invest; 2020 Aug; 43(8):1053-1060. PubMed ID: 32495299
[TBL] [Abstract][Full Text] [Related]
20. Bioactive compounds with possible inhibitory activity of Angiotensin-Converting Enzyme-II; a gate to manage and prevent COVID-19.
Dabaghian F; Khanavi M; Zarshenas MM
Med Hypotheses; 2020 Oct; 143():109841. PubMed ID: 32425303
[No Abstract] [Full Text] [Related]
[Next] [New Search]
